Pfizer is a global biopharmaceutical company that develops and manufactures innovative medicines and vaccines to improve health outcomes for people around the world. Renowned for its extensive research and development efforts, Pfizer focuses on various therapeutic areas including vaccines, oncology, immunology, cardiology, endocrinology, and rare diseases. The company is committed to addressing significant health challenges through the discovery of new treatments, leveraging cutting-edge science and technology. Pfizer also emphasizes partnerships and collaborations to expand its capabilities and enhance access to healthcare solutions. Read More
The United States government, after an unprecedented 43-day shutdown, officially reopened on Thursday, November 13, 2025, as President Donald Trump signed a funding bill into law. While the resolution brought an end to the longest federal government impasse in modern American history, the immediate reaction from financial markets was surprisingly
San Francisco, CA – November 13, 2025 – Artificial Intelligence (AI) has achieved a pivotal breakthrough in the medical field, successfully adjudicating clinical events in cardiovascular trials. This development marks a significant step forward in streamlining the notoriously complex and expensive process of bringing new therapies to patients, promising substantial reductions in costs and a [...]
Curious about the most active S&P500 stocks in today's session? Get insights into the stocks that are leading the way in terms of trading volume and market attention.
Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of Metsera, Inc. (NASDAQ: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases.
Wrapping up Q3 earnings, we look at the numbers and key takeaways for the generic pharmaceuticals stocks, including Viatris (NASDAQ:VTRS) and its peers.
New York, NY – November 12, 2025 – The Dow Jones Industrial Average (DJIA) surged by nearly 400 points today, hitting an unprecedented record high, as investors enthusiastically embraced the impending resolution of a protracted U.S. government shutdown. This significant market rally reflects a powerful wave of optimism sweeping through financial
Irvine, CA – November 12, 2025 – Eledon Pharmaceuticals (NASDAQ: ELDN) witnessed a significant decline in its stock value today, plummeting by 17.8% in premarket trading. This sharp drop comes on the heels of the company's announcement regarding the pricing of a $50 million underwritten public offering, a move that is
Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a discussion with Dave Denton, Chief Financial Officer, Executive Vice President, at the Jefferies London Healthcare Conference on Wednesday, November 19, 2025 at 9:00 a.m. GMT.
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around.
Without a clear path to profitability, these businesses risk running out of capital or relying on dilutive fundraising.
Large-cap stocks usually command their industries because they have the scale to drive market trends.
The flip side though is that their sheer size can limit growth as expanding further becomes an increasingly challenging task.
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid growing valuation concerns.
